December 12, 2025 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS), and Enhancing Oncology Model (EOM), and Advanced Care Planning (ACP).
MIPS Quality Measures Dashboard
The MIPS Quality Measures Dashboard will be updated to reflect the following refinement(s):
| Measure | Update | Practice Impact |
| MIPS 144: Pain Care Plan | Technical fix to ensure duplicate patients are not included in the denominator and numerator. Previously, there were G2 patients duplicated during the chart merger. | Practices will notice a decrease in Denominator and Numerator. |
| MIPS 450: Trastuzumab Received by Patients with AJCC Stage I (T1c), II, and III and HER2+ Breast Cancer Receiving Adjuvant Cancer | Technical fix to ensure HER2 status documentation is captured, and Denominator credit is attributed accurately. | Practices will notice an increase in Denominator and Numerator. |
| MIPS 451: RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal Antibody Therapy | Technical fix to ensure biomarker charting for KRAS/NRAS Mutation testing are accurately attributed to Numerator credit when documented. | Practices will notice an impact to their Numerator and performance rate. |
EOM VBC Navigation Summary Dashboard
Starting Monday, December 15, 2025, VBC Navigation Summary Dashboard will display ePRO Enrollment data and Genetic Counseling Referral data.
ePRO Enrollment
Genetic Counseling Referral
Advanced Care Planning Dashboards
Starting Monday, December 15, 2025, the Advance Care Planning Performance and Advance Care Planning Activities Dashboards will be updated with final data from Q2 2025.
Status of Dashboard Updates for 2025
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2025 requirements.
| Measure Number | Description |
| MIPS Quality Measures Dashboard | |
| MIPS #001 | Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure) |
| MIPS #047 | Advance Care Plan |
| MIPS #130 | Current Medications Documentation |
| MIPS #134 eCQM | Preventive Care Screening: Screening for Depression and Follow Up Plan |
| MIPS #134 CQM/Registry | Preventive Care Screening: Screening for Depression and Follow Up Plan |
| MIPS #143 | Pain Intensity Quantified |
| MIPS #144 | Pain Care Plan |
| MIPS #226 | Tobacco Screening and Cessation |
| MIPS #236 | Controlling High Blood Pressure |
| MIPS #238 | Use of High-Risk Medications in Older Adults (Inverse Measure) |
| MIPS #374 | Closing the Referral Loop |
| MIPS #450 | Appropriate Treatment for Patients with Stage I (T1c) III Her2 Positive Breast Cancer |
| MIPS #451 | RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal Antibody Therapy |
| MIPS #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
| MIPS #457 | Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days |
| MIPS #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
| MIPS #487 | Screening for Social Drivers of Health |
| PIMSH #1 | Advance Care Planning in Metastatic Disease |
| PIMSH #4 | Patient-Reported Pain Improvement |
| PIMSH #9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH #10 | Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
| PIMSH #13 | Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy |
| PIMSH #15 | Antiemetic Therapy for Low-and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure) |
| PIMSH #16 | Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center |
| PIMSH #17 | Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure) |
| PIMSH #18 | Resolution or Improvement of a Health-Related Social Need |
| EOM Performance Measures Dashboard | |
| EOM-4A | Pain Intensity Quantified |
| EOM-4B | Pain Care Plan |
| EOM-5 | Preventive Care Screening: Screening for Depression and Follow Up Plan |